论文部分内容阅读
目的：评价并比较非洛地平及赖诺普利治疗轻、中度原发性高血压（ＥＨ）的降压疗效及对左心室肥厚的逆转作用。方法：选择１２８例轻、中度ＥＨ患者，入选前服用安慰剂２周，随机分为非洛地平组６６例和赖诺普利组６２例。非洛地平组服用非洛地平５～１０ｍｇ／ｄ，赖诺普利组服用赖诺普利１０～２０ｍｇ／ｄ，每日１次，疗程２４周。两组均在治疗前及治疗后的２、１２、２４周分别进行偶测血压、２４ｈ动态血压及超声心动图检查。结果：非洛地平和赖诺普利均能显著降低血压，两药对偶测血压的下降幅度差异无显著性（Ｐ＞０．０５）。非洛地平能有效控制清晨高峰期血压。收缩压、舒张压的谷／峰比值分别是７２％、６７％。非洛地平降低２４ｈ平均血压和白昼血压的幅度大于赖诺普利，而夜间血压降低的幅度显著低于白昼。两药治疗２４周后，室间隔厚度、左心室后壁厚度、左室心肌重量及左室重量指数较治疗前显著改善（Ｐ＜０．００１）。两组药物副反应均较轻。结论：非洛地平能有效降低ＥＨ患者的血压，降低靶器官损害的危险性。
OBJECTIVE: To evaluate and compare the antihypertensive efficacy of felodipine and lisinopril in the treatment of mild to moderate essential hypertension (EH) and the reversal of left ventricular hypertrophy. Methods: A total of 128 patients with mild to moderate EH were enrolled in this study. Before placebo, they were given placebo for 2 weeks and were randomly divided into felodipine group (66 cases) and lisinopril group (62 cases). Felodipine group taking felodipine 5 ~ 10mg / d, lisinopril group taking lisinopril 10 ~ 20mg / d, once daily for 24 weeks. Both groups were measured before treatment and 2,12,24 weeks after treatment even measured blood pressure, 24h ambulatory blood pressure and echocardiography. Results: Both felodipine and lisinopril were able to significantly lower blood pressure, and there was no significant difference between the two drugs in decreasing blood pressure (P> 0.05). Felodipine can effectively control the early morning blood pressure. The systolic and diastolic valleys were 72% and 67%, respectively. Felodipine reduced 24h mean blood pressure and daytime blood pressure greater than lisinopril, while the magnitude of nighttime blood pressure was significantly lower than that of daytime. After 24 weeks of treatment, the thickness of the interventricular septum, the thickness of the left ventricular wall, the weight of the left ventricle and the weight of the left ventricle were significantly improved (P <0.001). Side effects of both groups were lighter. Conclusion: Felodipine can effectively reduce the blood pressure of EH patients and reduce the risk of target organ damage.